Subscribe to Newsletter
Subspecialties Oncology, Screening and monitoring, Precision medicine

Exploring MSI Screening Technologies

sponsored by Promega

Available On-Demand

December 14th 2020, 2pm GMT

Microsatellite Instability (MSI)-High has been identified as a biomarker for immune checkpoint inhibitor therapy in cancers originating in different tissues. As such, key opinion leaders have recommended MSI screening across all solid tumors. This Webinar will explore the biology of MSI; latest clinical practice guidelines around MSI screening; and a new tool to assess MSI status in Europe: the Promega OncoMate™ MSI Dx Analysis System, a PCR-based, validated gold standard for MSI status detection that provides analytical sensitivity and unsurpassed specificity with a short turn-around time.

Webinar Learning Objectives:

  • Discuss the biology of microsatellite instability (MSI), including the relation between MMR protein dysfunction and MSI
  • Provide overview of latest clinical practice guidelines regarding MSI screening in relevant tumor types
  • Introduce Promega OncoMate™ MSI Dx Analysis System, a PCR-based, validated gold standard for MSI status detection in Europe

Available On-Demand

Visit our Webinar Hub

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Related Application Notes
Tumor Genomic Profiling with SureSelect Cancer Tumor-Specific Assays

| Contributed by Agilent

Comprehensive Genomic Profiling with SureSelect Cancer CGP Assay

| Contributed by Agilent

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine